ArticleJournal of biochemical and molecular toxicology2026
Protective Effects of Gallic Acid in LPS-Induced Lung Injury via Modulation of Oxidative Stress: AKT1/NRF2 and IL-10 Signaling.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study investigated the protective effects of Gallic acid (GA) on Lipopolysaccharide (LPS)-induced acute lung injury (ALI), focusing on inflammatory cytokines and barrier integrity markers through histopathological, immunohistochemical, and genetic evaluations. Thirty-two adult male Wistar Albino rats were divided into Control, LPS, LPS + GA, and GA groups. LPS (5 mg/kg, intraperitoneal) induced ALI and GA (100 mg/kg, intraperitoneal) was administered to the treatment group. LPS caused hemorrhage, interalveolar septa thickening, inflammatory cell infiltration, and hyperemia. Interleukin (IL)-1β, IL-6, IL-17A, and glycogen synthase kinase-3 beta (GSK3β) increased, while IL-10, aquaporin 2 (AQP2), zonula occludens 1 (ZO-1), claudin 5 (Clau-5), serine/threonine kinase 1 (AKT1), and nuclear factor erythroid 2-related factor 2 (NRF2) decreased. GA reduced tissue damage and pro-inflammatory cytokines while restoring AKT1, NRF2, AQP2, ZO-1, and Clau-5. These findings suggest that GA attenuates LPS-induced lung injury and is associated with modulation of inflammatory and antioxidant-related signaling, including components of the IL-10-AKT1/GSK3β/NRF2 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.